T 1741/22 - no credible technical effect produced by deriving additional data from medical measurements

George James
September 19, 2024
#
EPO

An interesting "B" decision from Board 3.5.05 was published yesterday relating to the generation of new data from medical measurements being relied on for a technical effect. The decision is summarised with the catchword: "The mere generation of further data from measurement data already collected from the human body is not a technical effect (T 2681/16 and the Guidelines for Examination not followed)".

The patent at issue in T 1741/22 related to a system for analysing glucose monitoring data indicative of a glucose level in a bodily fluid. Most of the inventive step discussion revolved around Auxiliary Request 10, wherein the Patentee stated that the distinguishing features over the prior art were the steps involving determining and displaying minimum / maximum glucose values. In essence, the Patentee was arguing that "new data" was being generated from glucose monitoring data, which provided for improved analysis for guidance of a patient or physician. They even had an analogous case (T 2681/16) and an example in the Guidelines (G-II, 3.3) on their side!

The Board was not convinced. In their view, the claims did not relate to a new "measurement" with technical character, which must involve the calculation of the physical state of an object, such as the human or animal body (G 1/19). Rather, the claims involved processing already measured data to then generate and display further data. The Board found that such subsequent processing of certain measurement data amounts to merely cognitive or mathematical exercise that is inherently non-technical (reasons 2.3).

In the decision, the Board fully sets out why they have deviated from T 2681/16 (reasons 2.3.6) and also discusses the "clearly erroneous" section of the Guidelines (reasons 2.3.7).

All in all, the appeal was dismissed and the patent was revoked. We can perhaps expect a brief update to the Guidelines next year…

Recent Case Reports

Scripps mRNA reengineering patent found invalid and not infringed by Comirnaty
08 September 2026
The Local Division Munich invalidated Promosome's licensed mRNA patent over Scripps' codon-optimisation method, then found BioNTech's Comirnaty vaccine would not have infringed the claims even had they been valid.
Fujifilm v Kodak: clarifying the defence of dependent claims and inventive-step combinations at the UPC
27 August 2026
The Court of Appeal gave guidance on defending dependent claims, relying on EPO central limitation during UPC proceedings, and pleading revocation attacks. It also emphasised that inventive-step combinations require a proper pointer to the secondary reference.
Can Reference Numerals Influence Claim Interpretation?
21 August 2026
In T 0903/24, the EPO Board of Appeal relied on reference numerals to interpret disputed claim language, rejecting the patentee's narrower reading and revoking novelty over prior art D2 for the main request.